The Value of 18F-Fluorodeoxyglucose Positron Emission Tomography for Prediction of Treatment Response in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis Publisher Pubmed



Hassanzadehrad A¹ ; Yousefifard M³ ; Katal S¹ ; Asady H⁴ ; Fardesfahani A¹ ; Moghadas Jafari A⁶ ; Hosseini M^{2, 5}
Source: Journal of Gastroenterology and Hepatology (Australia) Published:2016

Abstract

Background: Early detection of response to treatment is critically important in gastrointestinal stromal tumors (GIST). Therefore, the present systematic review and meta-analysis assessed the value of 18f-fluorodeoxyglucose positron emission tomography (18FDG-PET) on prediction of therapeutic response of GIST patients to systemic treatments. Methods: The literature search was conducted using PubMed, SCOPUS, Cochrane, and Google Scholar databases, and review article references. Eligible articles were defined as studies included confirmed GIST patients who underwent 18FDG-PET as well as assessing the screening role of it. Results: Finally, 21 relevant articles were included. The analysis showed the pooled sensitivity and specificity of 18FDG-PET in evaluation of response to treatment of GIST patient were 0.90 (95% CI: 0.85-0.94; I2=52.59, P=0.001) and 0.62 (95% CI: 0.49-0.75; I2=69.7, P=0.001), respectively. In addition, the pooled prognostic odds ratio of 18FDG-PET for was 14.99 (95% CI, 6.42-34.99; I2=100.0, P<0.001). The Meta regression showed that sensitivity of 18FDG-PET was higher if the sample size of study was equal or more than 30 cases (sensitivity=0.93; 95% CI: 0.89-0.97), when using PET/CT (sensitivity=0.92; 95% CI: 0.89-0.97), and self-design criteria (sensitivity=0.93; 95% CI: 0.87-1.0). Conclusion: The present meta-analysis showed 18FDG-PET has a significant value in predicting treatment response in GIST patients. © 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.